Homepage
Author:
Skye Bioscience, Inc.
Posted Date:
May 20, 2026
Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1
Skye Bioscience, Inc.
May 20, 2026
UPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update
Skye Bioscience, Inc.
May 13, 2026
Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update
Skye Bioscience, Inc.
May 12, 2026
Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit
Skye Bioscience, Inc.
April 7, 2026
Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development
Skye Bioscience, Inc.
April 2, 2026
Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Skye Bioscience, Inc.
March 11, 2026
Skye Bioscience to Announce 2025 Financial Results and Business Update on March 10, 2026
Skye Bioscience, Inc.
March 5, 2026
Skye Reports Positive CBeyond Phase 2a Extension Interim Study Results for Nimacimab in Combination With Semaglutide
Skye Bioscience, Inc.
February 2, 2026
Skye Bioscience Highlights Attributes of its Peripherally-restricted CB1 Inhibitor Antibody at Keystone Obesity Conference
Skye Bioscience, Inc.
January 29, 2026
